Sen-Jam Pharmaceuticals, a New York-based biotech firm, announced on Tuesday that it has launched the Healthspan Catalyst Fund, offering new investment and philanthropic pathways to support its efforts in targeting inflammation-driven diseases. The company asserts that inflammation is responsible for 75% of chronic conditions and a key factor in declining health outcomes across the United States.

The fund provides two participation options: philanthropic contributions through CataCap, a 501(c)(3) intermediary administered by ImpactAssets, and community investment via a Regulation CF round on Wefunder. Investors, accredited or not, may enter with a minimum of USD250. The initiative aims to raise USD25,000 by 8 August 2025, triggering Sen-Jam's public listing on the CataCap platform.

Proceeds will support pre-clinical and clinical research focused on age-related, inflammation-based diseases and advance Sen-Jam's lead programme, a Phase 2 trial of SJP-001 for alcohol-related inflammation. The company claims its platform targets all five inflammatory pathways, offering low-cost, upstream treatment solutions with broad accessibility.